KRAS and adenocarcinoma: In the present study, 33% of patients diagnosed with adenocarcinoma were found with positive KRAS mutations whereas 10% in patients diagnosed with squamous cell carcinoma which is in accordance with previous studies reporting that KRAS mutations are more common in adenocarcinoma and less common in squamous cell carcinoma [14].